Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423348 | 1.00 | KDM4E (0.56) | KDM4EALDH1A1HPGDTDP1POLB | |
| SCHEMBL22263501 | 0.87 | PPARD (0.47) | KDM4EALDH1A1HPGDPPARDPPARA | |
| SCHEMBL29934771 | 0.85 | IKBKB (0.61) | KDM4EALDH1A1HPGDPPARDPPARA | |
| SCHEMBL6603045 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1HPGDPPARDPPARA | |
| SCHEMBL4432713 | 0.85 | IKBKB (0.61) | KDM4EALDH1A1HPGDPPARDPPARA | |
| SCHEMBL5789435 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1HPGDTDP1RAB9A | |
| SCHEMBL15945346 | 0.83 | SMN1; SMN2 (0.50) | KDM4EPPARDPPARARAB9AMAPT | |
| SCHEMBL15671177 | 0.83 | PPARD (0.45) | KDM4EALDH1A1HPGDPPARDPPARA | |
| SCHEMBL4228872 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1HPGDRAB9AMAPT | |
| SCHEMBL6604321 | 0.83 | PPARD (0.45) | KDM4EALDH1A1HPGDPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949559-A | Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators | 辉瑞公司 | 2018-04-20 | — | — | CN | claimed |
| CN-102414190-B | Inhibitors of NF-kB | PROFECTUS BIOSCIENCES INC | 2015-06-03 | — | — | CN | claimed |
| EP-2411376-B1 | INHIBITORS OF NF-KB | PROFECTUS BIOSCIENCES INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8629164-B2 | Inhibitors of NF-κB | PROFECTUS BIOSCIENCES, INC. (US) | 2014-01-14 | — | — | US | claimed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | claimed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | claimed |
| CN-119101045-A | Nitrogen-containing heterocyclic compounds, and preparation method and application thereof | 上海宇道生物技术有限公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-3558980-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2021-01-27 | — | — | EP | disclosed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | disclosed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | disclosed |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-03-26 | — | — | US | disclosed |
| EP-3558980-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2019-10-30 | — | — | EP | disclosed |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1412349-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | Schering Aktiengesellschaft (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002098856-A2 | PIPERAZINE OXYQUINOLINE (NAPHTHALINE) PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| US-5246945-A | 5-hydroxytryptamine antagonist for nervous system disorders | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0089597-A2 | Sulphonyl ureas, process for their preparation, pharmaceutical compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | NISCH, TK2, FDPS | KDM4E 933/4885ALDH1A1 1658/4885HPGD 115/4885 |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | NISCH, TK2, FDPS | KDM4E 933/4885ALDH1A1 1658/4885HPGD 115/4885 |
| US-20090054411-A1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | KDM4E 762/4885ALDH1A1 1650/4885HPGD 3611/4885 |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | KDM4E 1916/4885ALDH1A1 753/4885HPGD 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.